retatrutide mechanism gip glp-1 glucagon triple agonist Guide 2023: Weight Loss, Benefits, Results, Dosage Retatrutide (LY3437943): Mechanism of Action

Ballotari P, Vicentini M, Manicardi V, et al

A statistically significant improvement in fibrosis was also observed

Learn more about Tirzepatide dosage for weight loss

We identified detrimental metabolic effects following either the discontinuation of GLP-1 receptor agonist therapy or its substitution with DPP4i or SGLT2i treatments

Survodutide (BI 456906) is a GLP-1/glucagon co-agonist which has progressed to phase 3 clinical trials as treatment for obesity (SYNCHRONIZE programme)

Opportunities Growing Clinical Evidence of Cardiovascular and Renal Benefits is Creating Growth Opportunities Increasing clinical evidence highlighting the cardiovascular and renal benefits of certain GLP-1 receptor agonists is significantly driving their adoption